Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community. Listen here.

Meet the Laser Focus World Team

Editorial

Contact Sales

Editorial Advisory Board

Professor Andrea M. Armani, University of Southern California

Ruti Ben-Shlomi, Ph.D., LightSolver

James Butler, Ph.D., Hamamatsu

Natalie Fardian-Melamed, Ph.D., Columbia University

Justin Sigley, Ph.D., AmeriCOM

Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover

Professor Stephen Sweeney, University of Glasgow

Mohan Wang, Ph.D., University of Oxford

Professor Xuchen Wang, Harbin Engineering University

Professor Stefan Witte, Delft University of Technology

Bragar Eagel & Squire, P.C Continues Investigations on Behalf of Lineage, Proficient Auto, PetMed, and GeneDx and Encourages Investors to Contact the Firm

By: Bragar Eagel & Squire via GlobeNewswire

July 23, 2025 at 19:30 PM EDT

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed (PETS), GeneDx (WGS), Lineage (LINE), or Proficient Auto (PAL) To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Lineage, Inc. (NASDAQ: LINE), Proficient Auto Logistics, Inc. (NASDAQ: PAL), PetMed Express, Inc. (NASDAQ: PETS), and GeneDx Holdings Corp. (NASDAQ: WGS). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Lineage, Inc. (NASDAQ: LINE)
On April 30, 2025, Lineage reported first quarter 2025 financial results, including that “[t]otal revenue decreased (2.7)%” to $1.29 billion for the quarter. The Company stated it “experienced more normal seasonal trends in the first quarter after multiple years of elevated inventory levels.”

On this news, Lineage’s stock price fell $8.26, or 14.62%, to close at $48.23 per share on April 30, 2025, thereby injuring investors.

For more information on the Lineage investigation go to: https://bespc.com/cases/LINE

Proficient Auto Logistics, Inc. (NASDAQ: PAL)

On May 7, 2025, Proficient Auto announced financial results for its first quarter ended March 31, 2025, revealing that the Company had suffered a 0.4% year-over-year decrease in total operating revenue to $95.2 million and total operating loss of $2.4 million during the quarter.

On this news, Proficient Auto's stock price fell $0.40 per share, or 4.93%, to close at $7.72 per share on May 8, 2025.

For more information on the Semler investigation go to: https://bespc.com/cases/PAL

PetMed Express, Inc. (NASDAQ: PETS)

On June 10, 2025, PetMed issued a press release "announc[ing] it is delaying the release of the Company's fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process."

On this news, PetMed's stock price fell $0.47 per share, or 11.22%, to close at $3.72 per share on June 11, 2025.

For more information on the SelectQuote investigation go to: https://bespc.com/cases/PETS

GeneDx Holdings Corp. (NASDAQ: WGS)

On February 5, 2025, Grizzly Research ("Grizzly") published a report entitled "Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud". The Grizzly report asserted, among other things, that GeneDx's "growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue"; that "[t]estimonies from former employees and ongoing litigation suggest that GeneDx has inflated its revenue through an illegal practice known as ‘code stacking'", which "enables the company to bill insurance providers for services that do not meet the required criteria"; and that "CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, without ever engaging in open market purchases", a "pattern suggest[ing] that insiders may be aware of an imminent risk that will significantly impact the company."

On this news, GeneDx's stock price fell $4.84 per share, or 6.72%, to close at $67.18 per share on February 5, 2025.

For more information on the Cleveland-Cliffs investigation go to: https://bespc.com/cases/WGS

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com